Reduced cardiovascular risks in osteoporosis patients treated with FDA-approved romosozumab

Written by Lana Shkak, Commissioning Editor

Cardiovascular

A real-world data study led by pharmacoepidemiologist Jay Lin (Amgen, CA, USA) found that post-menopausal women taking romosozumab – marketed as Evenity – for osteoporosis did not experience a heightened risk of cardiovascular complications, such as stroke or myocardial infarction (MI). Originally, the FDA approved romosozumab as a monthly injection for those with post-menopausal osteoporosis with a high risk of bone fracture in April 2019. The packaging warned of an increased chance of cardiovascular complications and deaths, therefore patients who had suffered cardiovascular issues in the past year were advised against taking it. The findings of this study, presented at...

To view this content, please register now for access

It's completely free